Ayass, M.A.; Tripathi, T.; Griko, N.; Okyay, T.; Ramankutty Nair, R.; Zhang, J.; Zhu, K.; Melendez, K.; Pashkov, V.; Abi-Mosleh, L.
Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A. Cancers 2024, 16, 1041.
https://doi.org/10.3390/cancers16051041
AMA Style
Ayass MA, Tripathi T, Griko N, Okyay T, Ramankutty Nair R, Zhang J, Zhu K, Melendez K, Pashkov V, Abi-Mosleh L.
Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A. Cancers. 2024; 16(5):1041.
https://doi.org/10.3390/cancers16051041
Chicago/Turabian Style
Ayass, Mohamad Ammar, Trivendra Tripathi, Natalya Griko, Tutku Okyay, Ramya Ramankutty Nair, Jin Zhang, Kevin Zhu, Kristen Melendez, Victor Pashkov, and Lina Abi-Mosleh.
2024. "Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A" Cancers 16, no. 5: 1041.
https://doi.org/10.3390/cancers16051041
APA Style
Ayass, M. A., Tripathi, T., Griko, N., Okyay, T., Ramankutty Nair, R., Zhang, J., Zhu, K., Melendez, K., Pashkov, V., & Abi-Mosleh, L.
(2024). Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A. Cancers, 16(5), 1041.
https://doi.org/10.3390/cancers16051041